Skip to main content

New PE owner for Univar

Private equity giant Apollo has agreed to acquire the majority of Univar Solutions in an all-cash deal that values the company at about $8.1 billion. There is also an unspecified minority investment from a wholly owned subsidiary of the Abu Dhabi Investment Authority.

Shareholders will receive $36.15/share in cash, which represents a 20.6% premium to the company's undisturbed closing stock price on 22 November 2022 or 33.6% on the volume-weighted average for the 30 trading days ending on that date.

AGC and CatSci ally

Under a newly signed partnership, AGC Pharma Chemicals and CatSci will combine to offer the former’s expertise in GMP manufacturing from development and manufacturing through to commercial with the latter’s in chemical development, analytical development, crystallisation and solid form, pre-formulation and HPAPI capabilities.

Drug product centre opens

Following two years of construction work, CDMO Siegfried has officially opened its new development centre for drug products at its sites in Barberà del Vallès and El Masnou near Barcelona. About 40 specialist scientists will work there.

The centre features laboratories and pilot capacities, including dedicated facilities for highly potent oral solid dosage forms. Siegfried said that the opening also completes the successful integration of the two sites into its network. It originally acquired them from Novartis in 2020.

Solenis to acquire Diversey

Speciality chemicals manufacturer Solenis has agreed to buy cleaning, infection prevention and hygiene giant Diversey. The $4.6 billion all-cash deal should be completed in 2H, subject to approval by Diversey shareholders, and will remove Diversey from public ownership. Both boards have backed it.

Most SVHC users compliant, Enforcement Forum finds

An EU-wide project by ECHA’s Enforcement Forum carried out in 2021 has found that most users of substances of commonly controlled very high concern (SVHCs), mainly SMEs, already comply with the authorisation requirement to control risks.

The authorities of all 28 member countries undertook 690 inspections at 516 companies, mostly SVHCs. The most common SVHCs checked were chromium trioxide and strontium chromate, which are used mainly in surface treatment and chrome plating.

New large-volume peptide deal for Bachem

Bachem has signed a new framework agreement to provide large volumes of peptides to an unnamed customer following a joint development project. This covers “a committed volume at an equivalent value of over CHF 500 million for the five-year period of 2027-2031, with significant upside potential,” the company said.

This follows recent deals a previous large-volume contract for another unnamed customer worth CHF 175 million in 2023-4. The deal was announced in September 2022 and subsequently upgraded with a further work order for a minimum total of CHF 1 billion from 2025 to 2029.

Subscribe to Current issue